Abstract
Cardiac arrhythmias remain a major source of morbidity and mortality in developed countries. Antiarrhythmic drug therapy was traditionally the mainstay of cardiac arrhythmia treatment; however, drug therapy of cardiac arrhythmias has been plagued by incomplete efficacy and by potentially serious adverse reactions, of which the most worrisome has been a potential for malignant proarrhythmia and related effects to increase cardiac mortality. This article reviews the principal arrhythmia mechanisms and their ionic determinants, and discusses potential innovative approaches to new antiarrhythmic drug development, including the consideration of novel ionic targets, potential biophysical approaches and non-channel components involved in composing the arrhythmic substrate.
Keywords: sinoatrial node (san), pacemaker, re-excitation, early afterdepolarizations(eads), sarcoplasmic reticulum (sr), automaticity, sodium current, channels, ultra rapid delayed rectifier, antiarrhythmic therapy
Current Pharmaceutical Design
Title: Novel Targets for Cardiac Antiarrhythmic Drug Development
Volume: 11 Issue: 15
Author(s): John Christian Hesketh, Daniel Herrera, Stephen Zicha and Stanley Nattel
Affiliation:
Keywords: sinoatrial node (san), pacemaker, re-excitation, early afterdepolarizations(eads), sarcoplasmic reticulum (sr), automaticity, sodium current, channels, ultra rapid delayed rectifier, antiarrhythmic therapy
Abstract: Cardiac arrhythmias remain a major source of morbidity and mortality in developed countries. Antiarrhythmic drug therapy was traditionally the mainstay of cardiac arrhythmia treatment; however, drug therapy of cardiac arrhythmias has been plagued by incomplete efficacy and by potentially serious adverse reactions, of which the most worrisome has been a potential for malignant proarrhythmia and related effects to increase cardiac mortality. This article reviews the principal arrhythmia mechanisms and their ionic determinants, and discusses potential innovative approaches to new antiarrhythmic drug development, including the consideration of novel ionic targets, potential biophysical approaches and non-channel components involved in composing the arrhythmic substrate.
Export Options
About this article
Cite this article as:
Hesketh Christian John, Herrera Daniel, Zicha Stephen and Nattel Stanley, Novel Targets for Cardiac Antiarrhythmic Drug Development, Current Pharmaceutical Design 2005; 11 (15) . https://dx.doi.org/10.2174/1381612054021051
DOI https://dx.doi.org/10.2174/1381612054021051 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heart Failure and Diabetes: Perspective of a Dangerous Association
Current Hypertension Reviews Effects of Apelin Peptides on Diabetic Complications
Current Protein & Peptide Science Mouse Models of Autoimmune Diseases - Autoimmune Myocarditis
Current Pharmaceutical Design Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets
Current Pharmaceutical Design Covid-19: Pathophysiology; Mechanism of Transmission and Possible Molecular Drug Target for Management
Current Molecular Pharmacology Statins Attenuate Fibrotic Manifestations of Cardiac Tissue Damage
Current Molecular Pharmacology Pathomechanisms of Myocardial Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Targeting the Toll-System in Cardiovascular Sciences
Recent Patents on Inflammation & Allergy Drug Discovery Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design Antipsychotic-Induced Electrocardiographic Changes: A Comparative Study Between Olanzapine and Risperidone
Current Psychopharmacology Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine Nanotechnological Strategies for the Treatment of Neglected Diseases
Current Pharmaceutical Design Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Metabolic Therapy of Heart Failure
Current Pharmaceutical Design Mitochondrial Physiology and Toxicity (Mitotoxicity); Importance for the Immune System, Programmed Cell Death and Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Mitochondrial MMP Activation, Dysfunction and Arrhythmogenesis in Hyperhomocysteinemia
Current Vascular Pharmacology Role of Pharmacotherapy in Cardiac Ion Channelopathies
Current Vascular Pharmacology